Filing Analysis
Larimar Therapeutics, Inc. announced its second quarter 2026 financial results and operational highlights. The company also updated its corporate presentation for investor use.
📋 Key Facts
- Reported Q2 2026 financial results (ended June 30, 2026) on August 4, 2026.
- Released an updated corporate slide presentation to be used in meetings with investors and analysts.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Larimar Therapeutics announced the submission of its first module for a rolling Biologics License Application (BLA) to the FDA for nomlabofusp. The company also reported positive long-term data from an open-label study in patients with Friedreich’s ataxia.
📋 Key Facts
- Submitted the first module of a rolling BLA to the FDA for accelerated approval of nomlabofusp on June 29, 2026.
- Reported positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of nomlabofusp.
- The study involved adolescent and adult patients with Friedreich’s ataxia.
Larimar Therapeutics, Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Most notably, stockholders approved an amendment to nearly double the number of authorized shares of common stock from 115,000,000 to 215,000,000.
🚩 Red Flags
- The massive increase in authorized shares from 115 million to 215 million (when 103.8 million are already outstanding) strongly signals upcoming highly dilutive equity offerings.
📋 Key Facts
- As of the March 25, 2026 record date, there were 103,882,937 outstanding shares of common stock entitled to vote.
- Stockholders approved Proposal 5 to increase authorized shares of common stock from 115,000,000 to 215,000,000 (89,732,486 votes for, 1,046,555 against).
- Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt were elected as Class III directors to serve until the 2029 Annual Meeting.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Larimar Therapeutics reported its first quarter 2026 financial results and operational highlights. The company also released an updated corporate presentation for use in upcoming investor and analyst meetings.
📋 Key Facts
- Announced financial results for the first quarter ended March 31, 2026
- Updated corporate slide presentation released on May 14, 2026
- The filing includes a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2)
Larimar Therapeutics, Inc. (LRMR) reported its financial results and operational highlights for the fourth quarter and fiscal year ended December 31, 2025. The filing serves as a formal disclosure of the company's year-end performance via a furnished press release.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- The announcement was made on March 19, 2026
- The report includes operational highlights alongside financial data
- Information was furnished under Item 2.02 and is not deemed 'filed' for Section 18 purposes
Larimar Therapeutics, Inc. filed an updated corporate presentation on March 9, 2026, to be used in meetings with investors and analysts. The presentation was made available on the company's website and included as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 9, 2026, under Item 8.01 (Other Events).
- Exhibit 99.1 contains the updated Corporate Presentation dated March 9, 2026.
- The presentation is intended for use in upcoming meetings with investors, analysts, and other parties.
Larimar Therapeutics entered into an underwriting agreement for a public offering of 20,000,000 shares of common stock at $5.00 per share. The underwriters fully exercised their option for an additional 3,000,000 shares, resulting in expected net proceeds of approximately $107.6 million.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of 23,000,000 new shares
📋 Key Facts
- Offering of 20,000,000 shares of common stock at a public price of $5.00 per share
- Underwriters (J.P. Morgan and Guggenheim) fully exercised an option for 3,000,000 additional shares on February 26, 2026
- Total expected net proceeds are approximately $107.6 million after deducting discounts and expenses
- The offering is expected to close on February 27, 2026
- Joint bookrunning managers include J.P. Morgan Securities LLC and Guggenheim Securities, LLC
Larimar Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to its lead candidate, nomlabofusp, for the treatment of Friedreich’s ataxia. This designation is intended to expedite the development and review of the drug for both adults and children.
📋 Key Facts
- On February 24, 2026, the FDA granted Breakthrough Therapy Designation to nomlabofusp.
- The designation applies to the treatment of adults and children with Friedreich’s ataxia.
- The company updated its corporate presentation (Exhibit 99.2) for use in investor and analyst meetings.
- Nomlabofusp is the company's primary therapeutic candidate for this rare genetic disease.
Larimar Therapeutics entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2.5 million shares of common stock for 250,000 shares of Series A Convertible Preferred Stock. The transaction involves a conversion ratio of 1:10 and is expected to close on January 23, 2026.
🚩 Red Flags
- Potential dilution for existing common shareholders due to the 1:10 conversion ratio of preferred stock.
- The transaction involves an exchange of equity rather than cash, which can sometimes indicate a desire to preserve liquidity or manage debt/equity structures without immediate cash outlay.
📋 Key Facts
- Exchange Agreement dated January 21, 2026, with Blue Owl Healthcare Opportunities IV Public Investments LP.
- Stockholder will exchange 2,500,000 shares of Common Stock for 250,000 shares of Series A Convertible Preferred Stock.
- Series A Preferred Stock is 'toothless' (generally no voting rights) and participates pari passu with common stock in liquidation.
- Conversion ratio: Each share of Series A is convertible into 10 shares of Common Stock.
- The Company filed a Certificate of Amendment to increase authorized Series A shares from 250,000 to 500,000.
- Issuance relies on the Section 3(a)(9) exemption from registration under the Securities Act.
Larimar Therapeutics disclosed preliminary cash and liquidity positions as of December 31, 2025, via an updated corporate presentation. The company reported approximately $136.9 million in cash, cash equivalents, and marketable securities.
🚩 Red Flags
- Financial figures are unaudited and subject to change upon completion of year-end closing procedures.
📋 Key Facts
- As of December 31, 2025, the Company had approximately $136.9 million in cash, cash equivalents, and marketable securities.
- The financial data provided is unaudited and preliminary.
- The company has not yet completed quarter-end or year-end financial close processes for the period ended December 31, 2025.
- PricewaterhouseCoopers LLP has not audited or reviewed this preliminary data.
Larimar Therapeutics entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2.5 million shares of common stock for 250,000 shares of newly designated Series A 'toothless' convertible preferred stock.
🚩 Red Flags
- Potential dilution for existing common shareholders upon conversion of preferred stock (2.5M potential new common shares)
- The transaction involves a significant block of equity being restructured into convertible securities.
📋 Key Facts
- Exchange date: December 16, 2025
- Common Stock exchanged: 2,500,000 shares
- Preferred Stock issued: 250,000 shares of Series A Convertible Preferred Stock
- Conversion ratio: 1 share of Preferred Stock converts to 10 shares of Common Stock
- Conversion blocker: Initially set at 9.99% (can be increased to 19.99%)
- Preferred stock is 'toothless' (generally no voting rights, except for amendments)
- Liquidation preference: Pari passu with Common Stock
- Issuance relied on Section 3(a)(9) exemption from registration under the Securities Act of 1933
Larimar Therapeutics, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website. The filing serves as a mechanism to incorporate this presentation into their official SEC records for use in investor meetings.
📋 Key Facts
- The company posted an updated slide presentation on November 10, 2025.
- The presentation is attached as Exhibit 99.1.
- The presentation will be used by the company in meetings with investors and analysts.
Larimar Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal notice that operational highlights and financial performance data were released via press release.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 5, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and operational highlights.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Larimar Therapeutics, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website. The company intends to use this presentation for upcoming meetings with investors and analysts.
📋 Key Facts
- Company posted an updated slide presentation on October 14, 2025.
- The presentation is attached as Exhibit 99.1.
- The filing was signed by Dr. Carole S. Ben-Maimon, President and CEO.
Larimar Therapeutics announced positive long-term data from its open-label study of nomlabofusp for the treatment of Friedreich’s ataxia. The company also hosted a conference call to discuss regulatory updates and presented new clinical data.
📋 Key Facts
- Announced positive 25 mg and 50 mg dose data from an ongoing long-term open-label study.
- The study evaluates daily subcutaneous injections of nomlabofusp (self-administered or caregiver-administered).
- Target indication is Friedreich’s ataxia.
- Company held a conference call on September 29, 2025, to discuss regulatory updates and clinical data.
Larimar Therapeutics announced its second quarter 2025 financial results and operational highlights. The company also released an updated corporate presentation for investor relations purposes.
📋 Key Facts
- Reported Q2 2025 financial results (ended June 30, 2025) on August 14, 2025.
- Furnished a press release containing operational highlights as Exhibit 99.1.
- Released an updated corporate slide presentation via website/Exhibit 99.2 for investor meetings.
Larimar Therapeutics, Inc. entered into an underwriting agreement to conduct a public offering of common stock. The offering includes 18.75 million firm shares and 2.81 million optional shares, resulting in expected net proceeds of approximately $64.4 million.
🚩 Red Flags
- Significant equity dilution for existing shareholders due to the issuance of over 21 million new shares.
📋 Key Facts
- The company is issuing 18,750,000 firm shares at a price of $3.20 per share.
- Underwriters exercised the option for an additional 2,812,500 optional shares on July 30, 2025.
- Total expected net proceeds are approximately $64.4 million after discounts and expenses.
- The offering is being conducted under a previously effective Form S-3 registration statement (File No. 333-279275).
- Underwriters include Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities, Inc., and William Blair & Company, L.L.C.
Larimar Therapeutics announced preliminary cash and marketable securities balances as of June 30, 2025, in connection with a preliminary prospectus supplement. The company reported approximately $138.5 million in liquidity.
🚩 Red Flags
- Financial data is preliminary and unaudited; actual figures may vary upon completion of closing procedures.
📋 Key Facts
- As of June 30, 2025, the Company had approximately $138.5 million in cash, cash equivalents, and marketable securities.
- The financial data provided is preliminary, unaudited, and subject to change upon completion of quarter-end closing processes.
- The announcement was made via a preliminary prospectus supplement filed pursuant to Rule 424(b)(5).
- The company has not yet completed its quarter-end financial close for the period ended June 30, 2025.
Larimar Therapeutics, Inc. filed an 8-K to announce the posting of an updated corporate slide presentation on its website. This is a routine disclosure typically used for investor relations and upcoming meetings with analysts.
📋 Key Facts
- The company posted an updated slide presentation on June 23, 2025.
- The presentation (Exhibit 99.1) will be used in meetings with investors, analysts, and other parties.
- No material financial changes or structural corporate shifts were disclosed in this filing.
Larimar Therapeutics announced a regulatory update regarding FDA safety database recommendations for its Biologics License Application (BLA). The company is refining its submission timeline to incorporate recommended safety data from both adult and pediatric populations with Friedreich’s Ataxia.
🚩 Red Flags
- Regulatory delay: The need to include additional safety data from both adults and children implies a potential extension of the timeline for BLA submission compared to original projections.
📋 Key Facts
- FDA issued safety database recommendations for the BLA submission.
- The company will include recommended safety data from adults and children with Friedreich’s Ataxia.
- Submission timeline for the BLA is being refined to accommodate these requirements.
- Company hosted a conference call and presentation on June 23, 2025, to discuss the update.
Larimar Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on May 13, 2025. The meeting resulted in the election of a new Class II Director and the advisory approval of executive compensation and auditor ratification.
📋 Key Facts
- Held 2025 Annual Meeting of Stockholders virtually on May 13, 2025.
- Thomas E. Hamilton was elected to the Board of Directors as a Class II director (serving until the 2028 Annual Meeting).
- Stockholders approved, on an advisory basis, the 2024 compensation of named executive officers.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
Larimar Therapeutics, Inc. filed an 8-K to announce the publication of an updated corporate slide presentation on its website. The filing serves as a placeholder for investor relations communications.
📋 Key Facts
- The company released an updated corporate presentation dated May 5, 2025.
- The presentation is intended for use in meetings with investors, analysts, and other parties.
- The update was filed under Item 8.01 (Other Events).
Larimar Therapeutics, Inc. announced its financial results and operational highlights for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2025.
- Announcement date: April 30, 2025.
- The filing includes Exhibit 99.1 containing the full press release of financial results and operational highlights.
Larimar Therapeutics, Inc. announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2024. The company also updated its corporate presentation for investor relations purposes.
📋 Key Facts
- Report covers Q4 2024 and FY 2024 financial results.
- Results were announced on March 24, 2025.
- Company updated its corporate slide presentation (Exhibit 99.2) for investor meetings.
Larimar Therapeutics announced the granting of performance-based restricted stock units (PSUs) to its top executive team, including the CEO and CFO. The awards are tied to the achievement of specific regulatory milestones.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Grant date: January 22, 2025.
- Carole S. Ben-Maimon (CEO): Awarded 100,000 PSUs.
- Michael Celano (CFO): Awarded 50,000 PSUs.
- Gopi Shankar (CDO): Awarded 25,000 PSUs.
- Russell G. Clayton (CMO): Awarded 25,000 PSUs.
- Vesting is contingent upon achievement of regulatory milestones and a subsequent one-year anniversary.
Larimar Therapeutics, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website. The company intends to use this material in upcoming meetings with investors and analysts.
📋 Key Facts
- The filing was made on January 10, 2025.
- An updated corporate presentation dated January 10, 2025, was attached as Exhibit 99.1.
- The company intends to use the presentation for investor and analyst relations meetings.
Larimar Therapeutics announced positive initial data from its long-term open-label extension study for nomlabofusp in patients with Friedreich’s ataxia. The company also updated its corporate investor presentation.
📋 Key Facts
- Announced positive initial data from an ongoing long-term open-label extension study.
- Study evaluated daily subcutaneous injections of 25 mg of nomlabofusp (self-administered or caregiver-administered).
- Target indication: Friedreich’s ataxia.
- Released updated corporate investor presentation on December 16, 2024.
Larimar Therapeutics, Inc. filed an 8-K to announce the posting of a new corporate presentation on its website. This filing is intended to provide updated information for use in meetings with investors and analysts.
📋 Key Facts
- The company posted a slide presentation on its website dated November 18, 2024.
- The presentation is attached as Exhibit 99.1.
- The filing was signed by Dr. Carole S. Ben-Maimon, President and CEO.
Larimar Therapeutics, Inc. announced its third quarter 2024 financial results and operational highlights. The filing also includes an updated corporate presentation for investor relations purposes.
📋 Key Facts
- Reported financial results for the third quarter ended September 30, 2024.
- Released an updated corporate slide presentation on October 30, 2024.
- The filing is primarily a disclosure of quarterly earnings and operational updates.
Larimar Therapeutics, Inc. announced its second quarter 2024 financial results and operational highlights. The company also updated its corporate presentation for investor relations purposes.
📋 Key Facts
- Report covers the second quarter ended June 30, 2024.
- Financial results were furnished under Item 2.02 on August 7, 2024.
- Updated corporate slide presentation was posted to the company website (Exhibit 99.2).
- The filing includes a press release as Exhibit 99.1.
Larimar Therapeutics, Inc. filed an 8-K to announce the posting of an updated corporate slide presentation on its website. This is a routine disclosure often used to provide investors with current company information and strategic updates.
📋 Key Facts
- The filing was made on June 10, 2024.
- The Company posted an updated slide presentation (Exhibit 99.1) to its website.
- The presentation is intended for use in meetings with investors, analysts, and other parties.
Larimar Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on May 29, 2024. The filing reports the final voting results for several proposals, including director elections and auditor ratification.
📋 Key Facts
- Annual Meeting held virtually on May 29, 2024.
- Jonathan Leff and Jeffrey W. Sherman, M.D., FACP were elected to the Board of Directors as Class I directors serving until 2027.
- Stockholders approved the advisory compensation of named executive officers for 2023 (Say-on-Pay).
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- An amendment to the Ninth Amended and Restated Certificate of Incorporation regarding officer exculpation was approved.
- As of April 1, 2024, there were 63,800,017 outstanding shares entitled to vote.
Larimar Therapeutics announced that the FDA has selected its drug candidate, nomlabofusp, for participation in the START pilot program. This program is designed to support clinical trials for rare disease therapeutics.
📋 Key Facts
- FDA selected nomlabofusp for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.
- The announcement was made via press release on May 30, 2024.
- Nomlabofusp is being developed to treat a rare disease.
Larimar Therapeutics announced that the FDA has lifted a partial clinical hold on its nomlabofusp (CTI-1601) clinical program. The company also updated its corporate investor presentation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- FDA removed the partial clinical hold on the nomlabofusp (CTI-1601) clinical program on May 20, 2024.
- The announcement was made via a press release issued on May 20, 2024.
- Company updated its corporate slide presentation for investor use.
Larimar Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2024. The company also updated its corporate presentation to be used in investor meetings.
📋 Key Facts
- Report covers Q1 fiscal period ended March 31, 2024.
- Company furnished a press release containing financial results and operational highlights (Exhibit 99.1).
- Company updated its corporate slide presentation (Exhibit 99.2) for investor relations purposes.
Larimar Therapeutics, Inc. announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Reporting period: Q4 2023 and Full Year 2023
- Report date: March 14, 2024
- The filing includes a press release as Exhibit 99.1 containing financial results.
Larimar Therapeutics announced the dosing of the first patient in its open-label extension study for nomlabofusp (CTI-1601) to treat Friedreich’s ataxia. The company also released updated corporate and investor presentations.
📋 Key Facts
- First patient dosed in an open-label extension study evaluating 25 mg daily subcutaneous injections of nomlabofusp (CTI-1601).
- The clinical focus is on participants with Friedreich’s ataxia.
- Company released two new investor presentations via its website on March 11, 2024.
Larimar Therapeutics, Inc. completed a public offering of common stock to raise approximately $161.8 million in net proceeds. The offering included an over-allotment option that was fully exercised by the underwriters.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 19.7 million new shares.
📋 Key Facts
- The company entered into an underwriting agreement on February 14, 2024.
- Total shares offered: 17,162,472 common shares plus 2,574,370 additional shares via over-allotment option.
- Public offering price per share: $8.74.
- Net proceeds to the company: approximately $161.8 million (after discounts and expenses).
- Underwriters included Leerink Partners LLC, Citigroup Global Markets Inc., and Guggenheim Securities, LLC.
- The offering was conducted under a previously effective shelf registration statement on Form S-3.
Larimar Therapeutics terminated a $50 million 'at the market' sales agreement with Guggenheim Securities, LLC. The company had not utilized any portion of this equity offering facility prior to termination.
🚩 Red Flags
- Termination of a capital raising vehicle could suggest a shift in financing strategy or a change in market conditions, though no dilution occurred via this specific agreement.
📋 Key Facts
- Termination date: February 13, 2024.
- Agreement type: Sales Agreement for an 'at the market' (ATM) offering.
- Counterparty: Guggenheim Securities, LLC.
- Original agreement date: November 10, 2022.
- Aggregate offering amount: Up to $50,000,000 in common stock.
- Utilization status: No shares were sold under this agreement during its term.
Larimar Therapeutics announced its preliminary cash position as of December 31, 2023, reporting approximately $86.8 million in cash and marketable securities. Additionally, the company reported successful top-line data from a Phase 2 dose exploration study for nomlabofusp (CTI-1601) in treating Friedreich’s ataxia.
🚩 Red Flags
- Financial data is unaudited and subject to change during year-end closing procedures.
📋 Key Facts
- Cash, cash equivalents, and marketable securities totaled approximately $86.8 million as of December 31, 2023.
- The reported cash amount is unaudited and preliminary.
- Successful completion of a four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp (CTI-1601).
- Study focused on participants with Friedreich’s ataxia.